PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced today it has started an underwritten public offering of common stock and accompanying warrants (or pre-funded warrants in lieu of common stock). Certain investors may purchase pre-funded warrants instead of common stock, along with accompanying warrants. Cabaletta also plans to grant underwriters a 30-day option to buy up to an additional 15% of the shares and warrants offered. All securities in this offering are being sold by Cabaletta.
Jefferies, TD Cowen, and Cantor are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there is no guarantee on its size, terms, or completion.
The offering is expected to close on or around June 12, 2025, pending customary closing conditions.
The common stock, pre-funded warrants, and other securities are being offered under a shelf registration statement on Form S-3 (No. 333-278126), including amendments filed and declared effective on March 31, 2025. A preliminary prospectus supplement and accompanying prospectus outlining the offering terms will be filed with the SEC and available from Jefferies, TD Securities, or Cantor Fitzgerald.
The company declared that its announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.